Bioversys: ‘Impact investors should focus more on equitable health’

With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics. 

In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world. 

Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business.